# Axalta Coating Systems Ltd.: financial statements, quarterly

AXTA · NYSE · CIK 1616862 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/axta.md) · [Financials](/companies/axta/financials.md) · [Filings](/companies/axta/filings.md) · [Insiders](/companies/axta/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/axta/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,297 d](/filings/0001628280-26-008008.md) | [1,294](/filings/0001616862-25-000022.md) | [1,351](/filings/0001616862-25-000037.md) | [1,320](/filings/0001628280-25-047015.md) | [1,311 d](/filings/0001628280-26-008008.md) | [1,262](/filings/0001628280-26-028698.md) | [1,305](/filings/0001628280-26-050466.md) | [1,288](/filings/0001628280-26-068173.md) | [1,262 d](/filings/0001628280-26-008008.md) | [1,254](/filings/0001628280-26-028698.md) | [1,346](/filings/0001628280-26-050466.md) | [1,311](/filings/0001628280-26-068173.md) |
| Cost of revenue | $m | [874 d](/filings/0001628280-26-008008.md) | [865](/filings/0001616862-25-000022.md) | [891](/filings/0001616862-25-000037.md) | [858](/filings/0001628280-25-047015.md) | [864 d](/filings/0001628280-26-008008.md) | [829](/filings/0001628280-26-028698.md) | [848](/filings/0001628280-26-050466.md) | [838](/filings/0001628280-26-068173.md) | [840 d](/filings/0001628280-26-008008.md) | [838](/filings/0001628280-26-028698.md) | [881](/filings/0001628280-26-050466.md) | [877](/filings/0001628280-26-068173.md) |
| Research and development | $m | [18.0 d](/filings/0001628280-26-008008.md) | [18.0](/filings/0001616862-25-000022.md) | [18.0](/filings/0001616862-25-000037.md) | [19.0](/filings/0001628280-25-047015.md) | [19.0 d](/filings/0001628280-26-008008.md) | [17.0](/filings/0001628280-26-028698.md) | [20.0](/filings/0001628280-26-050466.md) | [18.0](/filings/0001628280-26-068173.md) | [16.0 d](/filings/0001628280-26-008008.md) | [18.0](/filings/0001628280-26-028698.md) | [18.0](/filings/0001628280-26-050466.md) | [18.0](/filings/0001628280-26-068173.md) |
| Selling, general and administrative | $m | [215 d](/filings/0001628280-26-008008.md) | [207](/filings/0001616862-25-000022.md) | [213](/filings/0001616862-25-000037.md) | [211](/filings/0001628280-25-047015.md) | [216 d](/filings/0001628280-26-008008.md) | [202](/filings/0001628280-26-028698.md) | [208](/filings/0001628280-26-050466.md) | [197](/filings/0001628280-26-068173.md) | [198 d](/filings/0001628280-26-008008.md) | [200](/filings/0001628280-26-028698.md) | [213](/filings/0001628280-26-050466.md) | [201](/filings/0001628280-26-068173.md) |
| Operating income | $m | [162 d](/filings/0001628280-26-008008.md) | [121](/filings/0001616862-25-000022.md) | [205](/filings/0001616862-25-000037.md) | [193](/filings/0001628280-25-047015.md) | [187 d](/filings/0001628280-26-008008.md) | [176](/filings/0001628280-26-028698.md) | [193](/filings/0001628280-26-050466.md) | [204](/filings/0001628280-26-068173.md) | [162 d](/filings/0001628280-26-008008.md) | [146](/filings/0001628280-26-028698.md) | [167](/filings/0001628280-26-050466.md) | [165](/filings/0001628280-26-068173.md) |
| Interest expense | $m | [55.1 d](/filings/0001628280-26-008008.md) | [54.0](/filings/0001616862-24-000035.md) | [50.0](/filings/0001616862-25-000037.md) | [54.0](/filings/0001628280-25-047015.md) | [47.0 d](/filings/0001628280-26-008008.md) | [44.0](/filings/0001628280-26-028698.md) | [45.0](/filings/0001628280-26-050466.md) | [45.0](/filings/0001628280-26-068173.md) | [42.0 d](/filings/0001628280-26-008008.md) | [38.0](/filings/0001628280-26-028698.md) | [37.0](/filings/0001628280-26-050466.md) | [37.0](/filings/0001628280-26-068173.md) |
| Income tax | $m | [28.0 d](/filings/0001628280-26-008008.md) | [20.0](/filings/0001616862-25-000022.md) | [43.0](/filings/0001616862-25-000037.md) | [40.0](/filings/0001628280-25-047015.md) | [2.0 d](/filings/0001628280-26-008008.md) | [30.0](/filings/0001628280-26-028698.md) | [33.0](/filings/0001628280-26-050466.md) | [45.0](/filings/0001628280-26-068173.md) | [59.0 d](/filings/0001628280-26-008008.md) | [14.0](/filings/0001628280-26-028698.md) | [45.0](/filings/0001628280-26-050466.md) | [33.0](/filings/0001628280-26-068173.md) |
| Net income | $m | [73.0 d](/filings/0001628280-26-008008.md) | [41.0](/filings/0001616862-25-000022.md) | [112](/filings/0001616862-25-000037.md) | [101](/filings/0001628280-25-047015.md) | [137 d](/filings/0001628280-26-008008.md) | [99.0](/filings/0001628280-26-028698.md) | [109](/filings/0001628280-26-050466.md) | [110](/filings/0001628280-26-068173.md) | [60.0 d](/filings/0001628280-26-008008.md) | [90.0](/filings/0001628280-26-028698.md) | [89.0](/filings/0001628280-26-050466.md) | [95.0](/filings/0001628280-26-068173.md) |
| Diluted EPS | $ per share | not reported | [0.18](/filings/0001616862-25-000022.md) | [0.51](/filings/0001616862-25-000037.md) | [0.46](/filings/0001628280-25-047015.md) | not reported | [0.45](/filings/0001628280-26-028698.md) | [0.50](/filings/0001628280-26-050466.md) | [0.51](/filings/0001628280-26-068173.md) | not reported | [0.42](/filings/0001628280-26-028698.md) | [0.41](/filings/0001628280-26-050466.md) | [0.44](/filings/0001628280-26-068173.md) |
| Basic EPS | $ per share | not reported | [0.18](/filings/0001616862-25-000022.md) | [0.51](/filings/0001616862-25-000037.md) | [0.46](/filings/0001628280-25-047015.md) | not reported | [0.45](/filings/0001628280-26-028698.md) | [0.50](/filings/0001628280-26-050466.md) | [0.51](/filings/0001628280-26-068173.md) | not reported | [0.42](/filings/0001628280-26-028698.md) | [0.42](/filings/0001628280-26-050466.md) | [0.44](/filings/0001628280-26-068173.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [700](/filings/0001628280-26-008008.md) | [624](/filings/0001616862-25-000022.md) | [840](/filings/0001616862-25-000037.md) | [567](/filings/0001628280-25-047015.md) | [593](/filings/0001628280-26-008008.md) | [575](/filings/0001628280-26-028698.md) | [625](/filings/0001628280-26-050466.md) | [606](/filings/0001628280-26-068173.md) | [657](/filings/0001628280-26-068173.md) | [608](/filings/0001628280-26-028698.md) | [633](/filings/0001628280-26-050466.md) | [650](/filings/0001628280-26-068173.md) |
| Current assets | $m | [2,821](/filings/0001616862-25-000013.md) | [2,760](/filings/0001616862-24-000035.md) | [3,014](/filings/0001616862-24-000056.md) | [2,838](/filings/0001616862-24-000065.md) | [2,723](/filings/0001628280-26-008008.md) | [2,821](/filings/0001616862-25-000022.md) | [2,987](/filings/0001616862-25-000037.md) | [2,991](/filings/0001628280-25-047015.md) | [2,815](/filings/0001628280-26-068173.md) | [2,827](/filings/0001628280-26-028698.md) | [2,990](/filings/0001628280-26-050466.md) | [3,063](/filings/0001628280-26-068173.md) |
| Total assets | $m | [7,272](/filings/0001616862-25-000013.md) | [7,089](/filings/0001616862-24-000035.md) | [7,306](/filings/0001616862-24-000056.md) | [7,500](/filings/0001616862-24-000065.md) | [7,249](/filings/0001628280-26-008008.md) | [7,411](/filings/0001616862-25-000022.md) | [7,781](/filings/0001616862-25-000037.md) | [7,760](/filings/0001628280-25-047015.md) | [7,599](/filings/0001628280-26-068173.md) | [7,558](/filings/0001628280-26-028698.md) | [7,699](/filings/0001628280-26-050466.md) | [7,747](/filings/0001628280-26-068173.md) |
| Current liabilities | $m | [1,428](/filings/0001616862-25-000013.md) | [1,332](/filings/0001616862-24-000035.md) | [1,335](/filings/0001616862-24-000056.md) | [1,422](/filings/0001616862-24-000065.md) | [1,354](/filings/0001628280-26-008008.md) | [1,330](/filings/0001616862-25-000022.md) | [1,406](/filings/0001616862-25-000037.md) | [1,360](/filings/0001628280-25-047015.md) | [1,369](/filings/0001628280-26-068173.md) | [1,348](/filings/0001628280-26-028698.md) | [1,950](/filings/0001628280-26-050466.md) | [2,000](/filings/0001628280-26-068173.md) |
| Total liabilities | $m | [5,499](/filings/0001616862-25-000013.md) | [5,314](/filings/0001616862-24-000035.md) | [5,488](/filings/0001616862-24-000056.md) | [5,549](/filings/0001616862-24-000065.md) | [5,293](/filings/0001628280-26-008008.md) | [5,289](/filings/0001616862-25-000022.md) | [5,470](/filings/0001616862-25-000037.md) | [5,435](/filings/0001628280-25-047015.md) | [5,206](/filings/0001628280-26-068173.md) | [5,091](/filings/0001628280-26-028698.md) | [5,130](/filings/0001628280-26-050466.md) | [5,081](/filings/0001628280-26-068173.md) |
| Long-term debt | $m | [3,478](/filings/0001616862-25-000013.md) | not reported | not reported | not reported | [3,401](/filings/0001628280-26-008008.md) | not reported | not reported | not reported | [3,179](/filings/0001628280-26-008008.md) | not reported | not reported | not reported |
| Current portion of debt | $m | [26.0](/filings/0001616862-25-000013.md) | [20.0](/filings/0001616862-24-000035.md) | [20.0](/filings/0001616862-24-000056.md) | [20.0](/filings/0001616862-24-000065.md) | [20.0](/filings/0001628280-26-008008.md) | [20.0](/filings/0001616862-25-000022.md) | [20.0](/filings/0001616862-25-000037.md) | [20.0](/filings/0001628280-25-047015.md) | [20.0](/filings/0001628280-26-068173.md) | [20.0](/filings/0001628280-26-028698.md) | [519](/filings/0001628280-26-050466.md) | [519](/filings/0001628280-26-068173.md) |
| Short-term borrowings | $m | [7.0](/filings/0001616862-25-000013.md) | [3.0](/filings/0001616862-24-000035.md) | [3.0](/filings/0001616862-24-000056.md) | [3.0](/filings/0001616862-24-000065.md) | [3.0](/filings/0001628280-26-008008.md) | [3.0](/filings/0001616862-25-000022.md) | [3.0](/filings/0001616862-25-000037.md) | [3.0](/filings/0001628280-25-047015.md) | [3.0](/filings/0001628280-26-068173.md) | [3.0](/filings/0001628280-26-028698.md) | [502](/filings/0001628280-26-050466.md) | [502](/filings/0001628280-26-068173.md) |
| Shareholders' equity | $m | [1,727](/filings/0001616862-25-000013.md) | [1,731](/filings/0001616862-24-000035.md) | [1,773](/filings/0001616862-24-000056.md) | [1,905](/filings/0001616862-24-000065.md) | [1,912](/filings/0001628280-26-008008.md) | [2,076](/filings/0001616862-25-000022.md) | [2,265](/filings/0001616862-25-000037.md) | [2,279](/filings/0001628280-25-047015.md) | [2,346](/filings/0001628280-26-068173.md) | [2,421](/filings/0001628280-26-028698.md) | [2,522](/filings/0001628280-26-050466.md) | [2,620](/filings/0001628280-26-068173.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [286 d](/filings/0001628280-26-008008.md) | [34.0](/filings/0001616862-25-000022.md) | [114 d](/filings/0001616862-25-000037.md) | [194 d](/filings/0001628280-25-047015.md) | [234 d](/filings/0001628280-26-008008.md) | [26.0](/filings/0001628280-26-028698.md) | [142 d](/filings/0001628280-26-050466.md) | [137 d](/filings/0001628280-26-068173.md) | [344 d](/filings/0001628280-26-008008.md) | [68.0](/filings/0001628280-26-028698.md) | [152 d](/filings/0001628280-26-050466.md) | [135 d](/filings/0001628280-26-068173.md) |
| Capital expenditure | $m | [33.0 d](/filings/0001628280-26-008008.md) | [22.0](/filings/0001616862-25-000022.md) | [23.0 d](/filings/0001616862-25-000037.md) | [33.0 d](/filings/0001628280-25-047015.md) | [62.0 d](/filings/0001628280-26-008008.md) | [43.0](/filings/0001628280-26-028698.md) | [45.0 d](/filings/0001628280-26-050466.md) | [50.0 d](/filings/0001628280-26-068173.md) | [58.0 d](/filings/0001628280-26-008008.md) | [50.0](/filings/0001628280-26-028698.md) | [48.0 d](/filings/0001628280-26-050466.md) | [46.0 d](/filings/0001628280-26-068173.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-26-008008.md) | not reported | not reported | [50.0 d](/filings/0001628280-25-047015.md) | [0.0 d](/filings/0001628280-26-008008.md) | not reported | not reported | [100 d](/filings/0001628280-26-068173.md) | [0.0 d](/filings/0001628280-26-008008.md) | not reported | not reported | [0.0 d](/filings/0001628280-26-068173.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [222](/filings/0001616862-24-000035.md) | [223](/filings/0001616862-24-000056.md) | [222](/filings/0001616862-24-000065.md) | [221](/filings/0001616862-25-000022.md) | [221](/filings/0001616862-25-000037.md) | [220](/filings/0001628280-25-047015.md) | [219](/filings/0001628280-26-028698.md) | [218](/filings/0001628280-26-050466.md) | [216](/filings/0001628280-26-068173.md) | [215](/filings/0001628280-26-028698.md) | [215](/filings/0001628280-26-050466.md) | [215](/filings/0001628280-26-068173.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 214,045,097 at 2026-10-22, from the cover of the [10-Q filed 2026-10-29](/filings/0001628280-26-068173.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 20:06 ET. No prices; not investment advice.